TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 6-45~2. Within 3 months (100 days) of diagnosis of T1DM based on ADA criteria~3. At least one diabetes-related autoantibody~4. Stimulated C-peptide level \>0.2 pmol/ml by MMTT conducted 21 days after diagnosis of T1DM and within 37 days of randomization~5. At least three months from last live immunization received and willing to forgo live vaccinations for three months following last dose of study treatment~Exclusion Criteria:~1. Immunodeficiency, chronic lymphopenia, active infection, positive PPD result or a history of malignancy~2. Serologic evidence of current or past HIV, Hepatitis B or C~3. Pregnancy, lactation, or intention of pregnancy while on study~4. Current use of immunosuppressive agents, or medications known to influence glucose tolerance or glycemic control~5. Current participation in another T1DM treatment study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Intravenous infusions of CTLA-4 Ig
- 2 (Type: PLACEBO_COMPARATOR): Intravenous infusions of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ST-elevation myocardial infarction subject to acute PCI or non-ST elevation myocardial infarction subject to PCI within 72 hours after start of chest pain and:~* Revascularization by PCI,~* Signs of decreased wall-motion in at least 3 of 16 segments of the left ventricle~* Dyspnoea at rest and one of the following:~pulmonary edema, pulmonary congestion,need for CPAP or ventilator, need for IC diuretics or oliguria.~Subgroup of patients in cardiogenic shock: Systolic BP below 90 after 1 hour of volume therapy.~Exclusion Criteria:~* Age below 20 years~* Heart rate above 120 bpm~* Septic shock~* ARDS~* Creatinine \>450 micromol/l~* Hepatic impairment~* Significant mechanical outlet obstruction~* Allergy against study drug medication~* Anaemia (Hb \<8 g/dl)~* Pregnancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): levosimendan
- 2 (Type: PLACEBO_COMPARATOR): Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Antipsychotic Efficacy of ITI-007

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia~* experiencing an acute exacerbation of psychosis~Exclusion Criteria:~* any subject unable to provide informed consent~* any female subject who is pregnant or breast-feeding~* any subject judged to be medically inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 40 mg ITI-007 (Type: EXPERIMENTAL): 40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
- 60 mg ITI-007 (Type: EXPERIMENTAL): 60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally as formulated capsules once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics to Prevent Relapse After Hospitalization for Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Capacity for written informed consent~* Currently admitted to a Sheppard Pratt inpatient or day hospital for symptoms of mania~* Primary Axis I diagnosis (DSM-IV) at time of admission of Bipolar I Disorder (single manic episode, most recent episode manic, or most recent episode mixed) OR Schizoaffective Disorder, Bipolar type (manic or mixed state)~* Proficient in the English language~* Available to come to Sheppard Pratt Towson for follow-up visits~* Participated previously in one of our screening studies~Exclusion Criteria:~* Diagnosis of mental retardation~* Symptoms of mania secondary to a general medical condition~* Any clinically significant or unstable medical disorder as determined by the investigators including congestive heart failure, abnormal liver function or disease, renal failure, acute pancreatitis, any diagnosis of cancer undergoing active treatment, HIV infection or other immunodeficiency condition~* History of IV drug use~* Primary diagnosis of substance abuse or dependence according to DSM-IV criteria within the last 3 months, or has a positive drug toxicity screen~* Participated in any investigational drug trial in the past 30 days~* Pregnant or planning to become pregnant during the study period~* Receipt of antibiotic medication within the previous 24 hours (as anaerobic organisms residing in the gastrointestinal tract may be minimally affected by antibiotics)~* Documented celiac disease (as such persons should be on a gluten-free diet as this is the standard care). Of note, we are not limiting the study to individuals with elevated levels of gliadin or casein antibodies as we intend to look at these levels as a predictor of response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Probiotic Supplement (Type: EXPERIMENTAL): The probiotic supplement compound will consist of capsules containing approximately 10\^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
- Inert Compound (Type: PLACEBO_COMPARATOR): The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Home Administration of FluMist by Parents/Caregivers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The primary caregiver must be 18 years of age or older and willing to give written informed consent for study participation~2. The primary caregiver must be the parent or legal guardian of all the children in living in the household~3. All the children in the household who are 2 through 17 years of age must receive their primary care in the clinic~4. All the children in the household who are 2 through 17 years of age must have private insurance that will provide for the cost of influenza vaccination~5. There must be at least one member of the household who is 2 through 17 years of age, presenting for care in the clinic, eligible to receive Live Attenuated Influenza Vaccine (LAIV) and whose primary care giver is willing to administer LAIV to them in the clinic with supervision~6. There must be at least one family member of the household who is 2 through 17 years of age, not presenting for care in the clinic, eligible to receive LAIV and whose primary care giver is willing to administer LAIV to them in the in-home setting~7. There must be a working refrigerator in the household~8. The primary caregiver must have a working telephone number and be willing to be contacted for study follow-up by telephone or e-mail~9. The primary caregiver is available for the entire study period - 12 days following the last dose of LAIV to be administered to a child~10. The primary caregiver must agree to complete a 30 minute post vaccination assessment and an 8 day diary following vaccination for each child receiving LAIV.~Exclusion Criteria:~1. Children in the family receive vaccine through Vaccines for Children program

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- FluMist (Type: EXPERIMENTAL): Subjects receiving vaccine at home

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study-related activity.~* Subject meets one or more criteria for the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.~* Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45 kg/m2.~* Subject has a Screening serum urate level ≥ 8 mg/dL.~* Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment.~Exclusion Criteria:~* Subject is unable to take colchicine for gout flare prophylaxis.~* Subject has a history or suspicion of kidney stones.~* Subject has any gastrointestinal disorder that affects motility and/or absorption.~* Subject had unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants.~* Subject has Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator.~* Subject has an estimated creatinine clearance \< 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the Screening period.~* Subject is taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing.~* Subject is unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RDEA3170 2.5 mg, 7.5 mg and 15 mg (Type: EXPERIMENTAL): RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
- RDEA3170 5 mg, 10 mg and 20 mg (Type: EXPERIMENTAL): RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Lozenges for Treatment of Recurrent Aphthous Stomatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18-45 years old, 2. Patients presenting with RAS with the following characteristics: a. Minor aphthous ulcers less than 48 hours' duration prior to enrolment, b. Size no greater than 10 mm in diameter, c. A history that ulcers normally more than 5 days to resolve without treatment. The inclusion criteria for group B is the same except age, children with RAS aged between 3 and 12 years were recruited for the study.~Exclusion Criteria:~* A known history of hypersensitivities, immunologic or systemic diseases, pregnancy, smoking,~* treatment with systemic steroid or other immunomodulatory agents within 1 month before the study~* use of nonsteroidal anti-inflammatory drugs or oral antihistamines within 1 month prior to the study~* treatment of the ulcer with any preparation or medication within 72 hours prior to the study~* treatment with systemic antibiotics within 2 weeks prior to the study and a history of adverse reactions to lactose or fermented milk products.~* Children with a positive family history of RAS were excluded.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- ChocBalls (Type: EXPERIMENTAL): (L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
- Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt) (Type: ACTIVE_COMPARATOR): Each 100 g contains:~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Para-vertebral Dexmedetomidine and the Incidence of Postoperative Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA II-III~* Adult~* Video-assisted thoracic surgery~Exclusion Criteria:~* Patient refusal~* Allergy to medication~* Coagulopathy~* Malformation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine is added to bupivacaine the paravertebral block
- Bupivacaine (Type: OTHER): Bupivacaine only in the paravertebral block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects who voluntarily sign the informed consent.~* Subject has successfully completed the treatment phase of the preceding open-label year 1 study.~Exclusion Criteria:~* Subject is using or will use investigational medications, except as approved by Abbott.~* Subject has prematurely discontinued his/her combination therapy administered in the preceding open-label year 1 study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-335 + rosuvastatin calcium (Type: EXPERIMENTAL): None
- ABT-335 + simvastatin (Type: EXPERIMENTAL): None
- ABT-335 + atorvastatin calcium (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to provide written informed consent.~* All individuals who will undergo TRUSP as part of their standard of care are eligible for study.~Exclusion Criteria:~* Men under 30 years of age~* Individuals whose rectal swab indicates that they harbor CS-GNB who cannot receive ciprofloxacin as pre-procedure prophylaxis for any reason~* Individuals whose rectal swab indicates that they harbor CR-GNB who cannot abide by the antimicrobial prophylaxis guidelines outlined in the study protocol for any reason~* Individuals who do not wish to complete the pre-procedure risk factor questionnaire or the two post-procedure phone questionnaires to assess for infectious complications

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Cipro-susceptible (Type: OTHER): Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
- Cipro-resistant (Type: ACTIVE_COMPARATOR): Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~* trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~* cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~* ceftriaxone 500 mg intramuscularly 2 hours before the procedure~* gentamicin 2mg/kg intramuscularly 2 hours before the procedure~* amikacin 5 mg/kg intramuscularly 2 hours before the procedure~* aztreonam 500 mg intramuscularly 2 hours before the procedure~* imipenem 500 mg intramuscularly 2 hours before the procedure~* ceftriaxone 2000 mg intravenously 1 hour before the procedure~* gentamicin 2 mg/kg intravenously 1 hour before the procedure~* amikacin 5mg/kg intravenously 1 hour before the procedure~* aztreonam 2000 mg intravenously 1 hour before the procedure~* imipenem 1000 mg intravenously 1 hour before the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14 to 21 weeks gestation, based on menstrual history and clinical exam (with or without ultrasound)~* Meet legal criteria to obtain abortion~* Present with closed cervical os and no vaginal bleeding~* Live fetus at time of presentation for service~* Have no contraindications to study procedures, according to provider~* Be able to consent to procedure, either by reading consent document or by having consent document read to her~* Be willing to follow study procedures~Exclusion Criteria:~* Known previous transmural uterine incision~* Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol~* Any contraindications to vaginal delivery, including placenta previa~* Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mifepristone+misoprostol (Type: EXPERIMENTAL): 200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
- misoprostol (Type: EXPERIMENTAL): 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with insulin requiring type 1 or type 2 diabetes for at least 24 months~* Current treatment with human insulin (either premix of short and long/intermediate acting insulin) in a twice daily treatment regimen preparation and/or self-mix for at least 12 months~* Body mass index (BMI) below or equal to 35.0 kg/m\^2~* HbA1c below or equal to 11.0%~Exclusion Criteria:~* Total daily insulin dose at least 1.4 IU/kg~* Treatment with oral hypoglycaemic agents within the month prior to inclusion~* Recurrent severe hypoglycaemia (as judged by the investigator)~* Active proliferative retinopathy~* Impaired renal function with creatinine at least 150 mcmol/l (1.7 mg/dl)~* History of pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete